Oculis is a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic conditions with significant unmet medical needs. Headquartered in Switzerland, Oculis is led by an experienced management team and supported by leading international healthcare investors.
Products, services, technology
- Privosegtor, a neuroprotective candidate in registrational trials for the treatment of optic neuropathies (AON and NAION);
- OCS-01, an eye drop in registrational trials for DME;
- Licaminlimab, a novel topical anti-TNFα in registrational trial to drive precision medicine in DED.
- http://www.oculis.com
- +41 21 711 39 70
- Send an email
- Louie-Anne Gauthier
